Igene Biotechnology, Inc.
IGNE · OTC
9/30/2010 | 6/30/2010 | 3/31/2010 | 12/31/2009 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | 850.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -4,187.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -8,043% |
| EPS Diluted | -0 | -0.001 | -0 | -0 |
| % Growth | 20% | -25% | -100% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |